

IDH3B Antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI15365

Product Information

Application	WB
Primary Accession	<u>043837</u>
Other Accession	<u>NM_006899</u> , <u>NP_008830</u>
Reactivity	Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Dog, Guinea Pig, Horse, Bovine
Predicted	Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Dog, Guinea Pig, Horse, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	42184

Additional Information

Gene ID	3420
Alias Symbol Other Names	FLJ11043, H-IDHB, MGC903, RP46 Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial, 1.1.1.41, Isocitric dehydrogenase subunit beta, NAD(+)-specific ICDH subunit beta, IDH3B
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-IDH3B antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	IDH3B Antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	IDH3B
Function	Plays a structural role to facilitate the assembly and ensure the full activity of the enzyme catalyzing the decarboxylation of isocitrate (ICT) into alpha-ketoglutarate. The heterodimer composed of the alpha (IDH3A) and beta (IDH3B) subunits and the heterodimer composed of the alpha (IDH3A) and gamma (IDH3G) subunits, have considerable basal activity but the full activity of the heterotetramer (containing two subunits of IDH3A, one of IDH3B and one of IDH3G) requires the assembly and cooperative function of both heterodimers.

References

Kim Y.-O.,et al.J. Biol. Chem. 274:36866-36875(1999). Ota T.,et al.Nat. Genet. 36:40-45(2004). Deloukas P.,et al.Nature 414:865-871(2001). Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. Bechtel S.,et al.BMC Genomics 8:399-399(2007).



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.